Conference Proceedings

Efficacy of tildrakizumab, an anti-IL23p19 monoclonal antibody, stratified by prior exposure to biologics in a randomized, placebo-controlled phase 3 clinical trial

Alexa Kimball, K Papp, S Tyring, R Sinclair, Anish Mehta, N Cichanowitz, Q Li, S Green, C La Rosa

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | MOSBY-ELSEVIER | Published : 2017

Grants

Funding Acknowledgements

This study was funded by Merck & Co., Inc.